Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Adverum, 4D Molecular Present Dueling Phase II Datasets In Wet AMD

Jul 17 2024

• By Joseph Haas

Human eye — Adverum, 4D Molecular each hope to bring a gene therapy to market for wet AMD • Source: Shutterstock

Related Content

Adverum Faces Rocky Road As It Switches Gears From DME To Wet AMD

Jul 23 2021

Finance Watch: Biopharma Public Offerings Fell In Q4, But Activity Is Booming In Q1

Feb 15 2024

Adverum Climbs Out Of Abyss With Promising Early Gene Therapy Data In Wet AMD

Feb 08 2024

4D Molecular Therapeutics Brings A New Dimension To Wet AMD

Feb 05 2024

Regeneron Sees Further Growth For Eylea HD As Reimbursement Path Gets Smoother

Feb 02 2024

Related Companies

Adverum Biotechnologies, Inc.

4D Molecular Therapeutics

Regeneron Pharmaceuticals, Inc.

Bayer AG

Additional Topics

Clinical Trials Gene Therapy Business Strategies Drug Approval Standards Research & Development Ophthalmic BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window